Effect of Montelukast Sodium Combined with Cetirizine and Budesonide in the Treatment of Children with Cough Variant Asthma
Objective:To explore the effect of Montelukast Sodium combined with Cetirizine and Budesonide in the treatment of cough variant asthma(CVA)in children.Method:A total of 92 children with CVA who admitted to Hanchuan Maternal and Child Health Hospital from January 2021 to January 2023 were selected as the study objects,and they were divided into the control group and the observation group according to the random number table method,with 46 cases in each group.The control group was treated with Budesonide,while the observation group was treated with Montelukast Sodium and Cetirizine on the basis of the control group.The remission time of clinical symptoms and the expression levels of immune indexes,inflammatory factors,miR-155 and miR-138 before and after treatment were compared between two groups.Result:The disappearance time of cough,disappearance time of high fever,and relief time of dyspnea of the observation group were earlier than control group,the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of helper T cell 1(Th1),helper T cell 2(Th2),Th1/Th2,serum interferon-γ(IFN-γ),interleukin-4(IL-4),interleukin-10(IL-10),and the expression levels of miR-155 and miR-138 between two groups(P>0.05);after treatment,the above indexes of two groups were improved to varying degrees compared with those before treatment,and the levels of Th1,Th1/Th2 and IFN-γ in the observation group were higher than those in the control group,while the levels of Th2,IL-4,IL-10,miR-155 and miR-138 were lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Montelukast Sodium combined with Cetirizine and Budesonide can effectively regulate Th1/Th2 balance of CVA,reduce inflammation levels,and also regulate the expression of miR-155 and miR-138 in peripheral blood,which is beneficial for symptom improvement and prognosis recovery.
万方数据
维普
